Results 51 to 60 of about 114,702 (262)

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. [PDF]

New England Journal of Medicine, 2014
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized.
J. Woyach, R. Furman, Ta-Ming Liu, H. Ozer, M. Zapatka, A. Ruppert, L. Xue, Daniel Li, S. Steggerda, M. Versele, S. Dave, Jenny Zhang, A. S. Yilmaz, S. Jaglowski, K. Blum, A. Lozanski, G. Lozanski, D. James, J. Barrientos, P. Lichter, S. Stilgenbauer, J. Buggy, B. Chang, A. Johnson, J. Byrd   +24 more
semanticscholar   +3 more sources

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [PDF]

, 2017
The Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side-effects of ibrutinib.
Appleby, Niamh, Bruce, David, Bye, Alex P., Desborough, Michael J., Gibbins, Jon M., Hildyard, Catherine A. T., Hughes, Craig E., Kriek, Neline, Nock, Sophie H., Sage, Tanya, Unsworth, Amanda J.   +10 more
core   +2 more sources

Novel Bruton’s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
D. Akasaka, Satoru Iguchi, R. Kaneko, Y. Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, F. Hosoi   +9 more
semanticscholar   +1 more source

Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies

British Journal of Haematology, 2020
Greater understanding of the mechanisms involved in the disease progression of haematological malignancies has led to the introduction of novel targeted therapies with reduced toxicity compared with chemotherapy‐based regimens, which has expanded the ...
A. Danilov, D. Persky
semanticscholar   +1 more source

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells [PDF]

, 2015
Background: Roughly 80% of patients with acute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the oral BTK inhibitor ibrutinib in vitro.
Advani, Bendall, Burger, Burnett, Byrd, Chung, Dasmahapatra, de Rooij, de Weers, Dohner, Dos Santos, Dubovsky, Döhner, Fiedler, Fiedler, Gao, Gu, Hahn, Honda, Horwood, Ikeda, Ito, Juliusson, Kim, Koketsu, Kvinlaug, Ma, Matsunaga, Meng, Miettinen, Oellerich, Rushworth, Rushworth, Rushworth, Rushworth, Rushworth, Schmidt, Sivina, Sun, Tai, Tomasson, Wang, Wang, Welch   +43 more
core   +1 more source

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & Rheumatology, 2021
Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter,
D. Isenberg, R. Furie, N. S. Jones, P. Guibord, J. Galanter, Chin H Lee, A. Mcgregor, Balazs Toth, J. Rae, O. Hwang, Rupal H Desai, A. Lokku, N. Ramamoorthi, J. Hackney, P. Miranda, Viviane A de Souza, J. Jaller-Raad, A. Maura Fernandes, Rodrigo García Salinas, L. Chinn, M. Townsend, A. Morimoto, K. Tuckwell   +22 more
semanticscholar   +1 more source

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

ACR Open Rheumatology, 2022
Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of evobrutinib in ...
D. Wallace, T. Dörner, D. Pisetsky, J. Sánchez-Guerrero, Anand C Patel, Dana Parsons-Rich, Claire Le Bolay, E. Drouin, A. Kao, H. Guehring, M. Dall'Era   +10 more
semanticscholar   +1 more source

Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib

Expert Review of Clinical Pharmacology, 2021
Introduction: Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, for
C. Tam, Y. Ou, J. Trotman, Stephen Samuel Opat   +3 more
semanticscholar   +1 more source

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma

Molecular Therapy: Oncolytics, 2021
Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials ...
Hui Yu, Xing Wang, Jiao Li, Yingying Ye, Dedao Wang, Wei Fang, Lan Mi, Ning Ding, Xiaogan Wang, Yuqin Song, Jun Zhu   +10 more
doaj   +1 more source